Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Ocular Therapeutix™ Announces FDA Acceptance of NDA Resubmission for DEXTENZA®July 19, 2018 8:00 AM